First-in-human PET neuroimaging of [¹⁸F]OXD-2314.

ABSTRACT:

Purpose

This first-in-human positron emission tomography (PET) study evaluates [¹⁸F]OXD-2314, a radiopharmaceutical designed for imaging tau in non-Alzheimer's disease tauopathies.

Methods

Synthesis of [¹⁸F]OXD-2314 was automated using a commercial module and validated for human use. Dynamic PET imaging was performed in healthy control subjects (2 female, 2 male, ages 49-65 years). Kinetic modelling was performed from brain time-activity curves and radiometabolite-corrected arterial input functions to estimate total distribution volumes (V_T) in each region of interest.

Results

[¹⁸F]OXD-2314 met all release criteria for human use. PET imaging revealed an initial whole brain peak of 2.3 standardized uptake value, followed by a

SUBMITTER: Murrell E 

PROVIDER: S-EPMC12660345 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature